Onco Wiki / Biomarker

HCV-Status (Anti-HCV-Antikörper-Screening)

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDBIO-HCV-STATUS
ArtBiomarker
Aliase
HCV-SerologieHepatitis C-ScreeningHepatitis C-VirusstatusAnti-HCV-VerfahrenСтатус HCV (антитіла анти-HCV)
Statusreviewed 2026-04-26 | pending_clinical_signoff
ErkrankungenDIS-DLBCL-NOS DIS-HCC DIS-MM DIS-NODAL-MZL DIS-SPLENIC-MZL
QuellenSRC-EASL-HCV-2023 SRC-NCCN-BCELL-2025

Biomarker-Fakten

Biomarker-Typviral_serology
Messung
VerfahrenAnti-HCV antibody (third-generation EIA). Reflex to BIO-HCV-RNA (quantitative PCR) when anti-HCV+ to distinguish active infection (RNA detectable) from resolved / cleared (RNA undetectable, antibody persists for life).
Einheitencategorical: anti-HCV+ | anti-HCV-
Verwandte BiomarkerBIO-HCV-RNA BIO-HBV-STATUS BIO-HIV-STATUS

Anmerkungen

Screening test; positive result is necessary but not sufficient evidence of active HCV (false positives in autoimmune disease, cleared infections retain antibodies indefinitely). Active infection requires BIO-HCV-RNA detectable; rules engine should branch on HCV-RNA positivity, not antibody alone, for any DAA / treatment decision. Currently consumed by: ALGO-MM-1L (etiology rail — coordinate DAA with hepatologist if HCV+). Companion biomarker BIO-HCV-RNA carries the quantitative load and drives the HCV-MZL etiologically-driven algorithm. STATUS is the cheap screening; RNA is the actionable confirmation. reviewer_signoffs: 0 # STUB — pending two Clinical Co-Lead approvals

Verwendet von

Algorithmen

Biomarker

Kapitel des Handbuchs

Anwendungsgebiet

Fragebogen